SCHEMBL957414

SCHEMBL957414

CC(C)S(=O)(=O)N[C@H]1Cc2ccc(Oc3ccccc3)cc2C1

nearest known ligand 0.54

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
GRIA2 P42262 20/20 0.54
CYP1A2 P05177 1/20 0.54
CYP2C19 P33261 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11900127 0.87 GRIA2 (0.56) GRIA2CYP1A2CYP2C19
SCHEMBL7897118 0.87 GRIA2 (0.56) GRIA2CYP1A2CYP2C19
SCHEMBL11898789 0.86 GRIA2 (0.72) GRIA2CYP1A2CYP2C19
SCHEMBL7896400 0.86 GRIA2 (0.55) GRIA2CYP1A2CYP2C19
SCHEMBL11898784 0.86 GRIA2 (0.55) GRIA2CYP1A2CYP2C19
SCHEMBL7900759 0.86 GRIA2 (0.72) GRIA2CYP1A2CYP2C19
SCHEMBL7892099 0.85 GRIA2 (0.60) GRIA2CYP1A2
SCHEMBL11899724 0.85 GRIA2 (0.60) GRIA2CYP1A2
SCHEMBL11898562 0.85 GRIA2 (0.54) GRIA2CYP1A2CYP2C19
SCHEMBL7899596 0.85 GRIA2 (0.51) GRIA2CYP1A2CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8173820-B2 Compounds which potentiate the AMPA receptor and uses thereof in medicine GLAXO GROUP LIMITED (GB) 2012-05-08 US claimed
US-20110021578-A1 Compounds which Potentiate the AMPA Receptor and Uses Thereof in Medicine GLAXO GROUP LIMITED (GB) 2011-01-27 US claimed
EP-2222632-A1 COMPOUNDS WHICH POTENTIATE THE AMPA RECEPTOR AND USES THEREOF IN MEDICINE Glaxo Group Limited (GB) 2010-09-01 EP claimed
WO-2010066658-A1 COMPOUNDS WHICH POTENTIATE THE AMPA RECEPTOR AND USES THEREOF IN MEDICINE GLAXO GROUP LIMITED (GB) 2010-06-17 WO claimed
WO-2009080637-A1 COMPOUNDS WHICH POTENTIATE THE AMPA RECEPTOR AND USES THEREOF IN MEDICINE GLAXO GROUP LIMITED (GB) 2009-07-02 WO claimed
US-8173820-B2 Compounds which potentiate the AMPA receptor and uses thereof in medicine GLAXO GROUP LIMITED (GB) 2012-05-08 US disclosed
US-8173820-B2 Compounds which potentiate the AMPA receptor and uses thereof in medicine GLAXO GROUP LIMITED (GB) 2012-05-08 US disclosed
US-20110021578-A1 Compounds which Potentiate the AMPA Receptor and Uses Thereof in Medicine GLAXO GROUP LIMITED (GB) 2011-01-27 US disclosed
US-20110021578-A1 Compounds which Potentiate the AMPA Receptor and Uses Thereof in Medicine GLAXO GROUP LIMITED (GB) 2011-01-27 US disclosed
EP-2222632-A1 COMPOUNDS WHICH POTENTIATE THE AMPA RECEPTOR AND USES THEREOF IN MEDICINE Glaxo Group Limited (GB) 2010-09-01 EP disclosed
WO-2009080637-A1 COMPOUNDS WHICH POTENTIATE THE AMPA RECEPTOR AND USES THEREOF IN MEDICINE GLAXO GROUP LIMITED (GB) 2009-07-02 WO disclosed
WO-2009080637-A1 COMPOUNDS WHICH POTENTIATE THE AMPA RECEPTOR AND USES THEREOF IN MEDICINE GLAXO GROUP LIMITED (GB) 2009-07-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110021578-A1 Compounds which Potentiate the AMPA Receptor and Uses Thereof in Medicine GRIN1, GRM1, GRM2 GRIA2 20/4885CYP1A2 1001/4885CYP2C19 949/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.